Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 89
Filter
1.
Radiother Oncol ; 190: 109953, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37839557

ABSTRACT

BACKGROUND AND PURPOSE: The FLASH effect has been validated in different preclinical experiments with electrons (eFLASH) and protons (pFLASH) operating at an average dose rate above 40 Gy/s. However, no systematic intercomparison of the FLASH effect produced by eFLASHvs. pFLASH has yet been performed and constitutes the aim of the present study. MATERIALS AND METHODS: The electron eRT6/Oriatron/CHUV/5.5 MeV and proton Gantry1/PSI/170 MeV were used to deliver conventional (0.1 Gy/s eCONV and pCONV) and FLASH (≥110 Gy/s eFLASH and pFLASH) dose rates. Protons were delivered in transmission. Dosimetric and biologic intercomparisons were performed using previously validated dosimetric approaches and experimental murine models. RESULTS: The difference between the average absorbed dose measured at Gantry 1 with PSI reference dosimeters and with CHUV/IRA dosimeters was -1.9 % (0.1 Gy/s) and + 2.5 % (110 Gy/s). The neurocognitive capacity of eFLASH and pFLASH irradiated mice was indistinguishable from the control, while both eCONV and pCONV irradiated cohorts showed cognitive decrements. Complete tumor response was obtained after an ablative dose of 20 Gy delivered with the two beams at CONV and FLASH dose rates. Tumor rejection upon rechallenge indicates that anti-tumor immunity was activated independently of the beam-type and the dose-rate. CONCLUSION: Despite major differences in the temporal microstructure of proton and electron beams, this study shows that dosimetric standards can be established. Normal brain protection and tumor control were produced by the two beams. More specifically, normal brain protection was achieved when a single dose of 10 Gy was delivered in 90 ms or less, suggesting that the most important physical parameter driving the FLASH sparing effect might be the mean dose rate. In addition, a systemic anti-tumor immunological memory response was observed in mice exposed to high ablative dose of electron and proton delivered at CONV and FLASH dose rate.


Subject(s)
Biological Products , Neoplasms , Proton Therapy , Humans , Animals , Mice , Protons , Electrons , Radiotherapy Dosage , Radiometry
2.
bioRxiv ; 2023 Apr 21.
Article in English | MEDLINE | ID: mdl-37131769

ABSTRACT

Background and purpose: The FLASH effect has been validated in different preclinical experiments with electrons (eFLASH) and protons (pFLASH) operating at a mean dose rate above 40 Gy/s. However, no systematic intercomparison of the FLASH effect produced by e vs. pFLASH has yet been performed and constitutes the aim of the present study. Materials and methods: The electron eRT6/Oriatron/CHUV/5.5 MeV and proton Gantry1/PSI/170 MeV were used to deliver conventional (0.1 Gy/s eCONV and pCONV) and FLASH (≥100 Gy/s eFLASH and pFLASH) irradiation. Protons were delivered in transmission. Dosimetric and biologic intercomparisons were performed with previously validated models. Results: Doses measured at Gantry1 were in agreement (± 2.5%) with reference dosimeters calibrated at CHUV/IRA. The neurocognitive capacity of e and pFLASH irradiated mice was indistinguishable from the control while both e and pCONV irradiated cohorts showed cognitive decrements. Complete tumor response was obtained with the two beams and was similar between e and pFLASH vs. e and pCONV. Tumor rejection was similar indicating that T-cell memory response is beam-type and dose-rate independent. Conclusion: Despite major differences in the temporal microstructure, this study shows that dosimetric standards can be established. The sparing of brain function and tumor control produced by the two beams were similar, suggesting that the most important physical parameter driving the FLASH effect is the overall time of exposure which should be in the range of hundreds of milliseconds for WBI in mice. In addition, we observed that immunological memory response is similar between electron and proton beams and is independent off the dose rate.

3.
Encephale ; 49(5): 525-531, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37005191

ABSTRACT

OBJECTIVES: Nightmares can be defined as "an unpleasant dream with anxiety and oppression". They represent a symptom possibly leading to serious psychiatric and physical consequences. It occurs to 2% to 8% of the general population. Lucid dreaming therapy (LDT) is an interesting upcoming psychotherapy for the treatment of nightmares. The aim of this study was to evaluate the efficacy of LDT in the treatment of nightmares in adults and children. METHODS: We performed a systematic review of the literature, based on the Cochrane organisation's methodology. We explored the PubMed, Cochrane library, PsycINFO via Ovid and Embase databases and clinical trial registries (CTR), namely clinicaltrials.gov, EU clinical trials and the WHO clinical trials registry platform. RESULTS: Four randomized controlled trials (RCT), 2 case series and 5 case reports were included. Most of the included studies found LDT effective in reducing nightmare frequency among adults with chronic and recurring nightmares. We did not identify any reports in children. CONCLUSIONS: Despite a limited internal validity for the included studies, these first results are encouraging. Nonetheless, larger and more rigorous studies would allow to better assess the utility of LDT for nightmares.


Subject(s)
Dreams , Mental Disorders , Adult , Child , Humans , Dreams/psychology , Psychotherapy/methods , Anxiety
4.
BMC Cancer ; 21(1): 805, 2021 Jul 13.
Article in English | MEDLINE | ID: mdl-34256713

ABSTRACT

BACKGROUND: Cancerous cells can recycle metabolic ammonium for their growth. As this ammonium has a low nitrogen isotope ratio (15N/14N), its recycling may cause cancer tissue to have lower 15N/14N than surrounding healthy tissue. We investigated whether, within a given tissue type in individual mice, tumoral and healthy tissues could be distinguished based on their 15N/14N. METHODS: Micro-biopsies of murine tumors and adjacent tissues were analyzed for 15N/14N using novel high-sensitivity methods. Isotopic analysis was pursued in Nude and C57BL/6 mice models with mature orthotopic brain and head&neck tumors generated by implantation of H454 and MEERL95 murine cells, respectively. RESULTS: In the 7 mice analyzed, the brain tumors had distinctly lower 15N/14N than healthy neural tissue. In the 5 mice with head&neck tumors, the difference was smaller and more variable. This was at least partly due to infiltration of healthy head&neck tissue by tumor cells. However, it may also indicate that the 15N/14N difference between tumoral and healthy tissue depends on the nitrogen metabolism of the healthy organ in question. CONCLUSIONS: The findings, coupled with the high sensitivity of the 15N/14N measurement method used here, suggest a new approach for micro-biopsy-based diagnosis of malignancy as well as an avenue for investigation of cancer metabolism.


Subject(s)
Biopsy/methods , Brain/physiopathology , Head and Neck Neoplasms/physiopathology , Nitrogen Isotopes/metabolism , Animals , Case-Control Studies , Disease Models, Animal , Humans , Mice , Mice, Nude
5.
Qual Life Res ; 28(3): 663-676, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30511255

ABSTRACT

PURPOSE: Using the EORTC Global Health Status (GHS) scale, we aimed to determine minimal clinically important differences (MCID) in health-related quality of life (HRQOL) changes for older cancer patients with a geriatric risk profile, as defined by the geriatric 8 (G8) health screening tool, undergoing treatment. Simultaneously, we assessed baseline patient characteristics prognostic for HRQOL changes. METHODS: Our analysis included 1424 (G8 ≤ 14) older patients with cancer scheduled to receive chemotherapy (n = 683) or surgery (n = 741). Anchor-based methods, linking the GHS score to clinical indicators, were used to determine MCID between baseline and follow-up at 3 months. A threshold of 0.2 standard deviation (SD) was used to exclude MCID estimates too small for interpretation. Logistic regressions analysed baseline patient characteristics prognostic for HRQOL changes. RESULTS: The 15-item Geriatric Depression Scale (GDS15), Visual Analogue Scale (VAS) for Fatigue and ECOG Performance Status (PS) were selected as clinical anchors. In the surgery group, MCID estimates for improvement and deterioration were ECOG PS (5*, 11*), GDS15 (5*, 2) and VAS Fatigue (3, 9*). In the chemotherapy group, MCID estimates for improvement and deterioration were ECOG PS (8*, 7*), GDS15 (5, 4) and VAS Fatigue (5, 5*). Estimates with * were > 0.2 SD threshold. Patients experiencing pain or malnutrition (surgery group) or fatigue (chemotherapy group) at baseline showed a significantly stable or improved HRQOL (p < 0.05) after their treatment. CONCLUSION: The reported MCID for improvement and deterioration depended on the anchor used and treatment received. The estimates can be used to evaluate significant changes in HRQOL and to determine sample sizes in clinical trials.


Subject(s)
Geriatric Assessment/methods , Health Status , Minimal Clinically Important Difference , Neoplasms/therapy , Quality of Life/psychology , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Female , Humans , Male , Middle Aged , Pain/pathology , Pain Measurement/methods , Surveys and Questionnaires
6.
Ann Oncol ; 29(9): 1987-1994, 2018 09 01.
Article in English | MEDLINE | ID: mdl-29905766

ABSTRACT

Background: In the general older population, geriatric assessment (GA)-guided treatment plans can improve overall survival, quality of life and functional status (FS). In GA-related research in geriatric oncology, studies mainly focused on geriatric screening and GA but not on geriatric recommendations, interventions and follow-up. The aim of this study was to investigate the adherence to geriatric recommendations and subsequent actions undertaken in older patients with cancer. Patient and methods: A prospective Belgian multicenter (N = 22) cohort study included patients ≥70 years with a malignant tumor upon oncologic treatment decision. Patients with an abnormal result on the geriatric screening (G8 ≤14/17) underwent GA. Geriatric recommendations were formulated based on GA results. At follow-up the adherence to geriatric recommendations was documented including a description of actions undertaken. Results: From November 2012 till February 2015, G8 screening was carried out in 8451 patients, of which 5838 patients had an abnormal result. Geriatric recommendations data were available for 5631 patients. Geriatric recommendations were made for 4459 patients. Geriatric interventions data were available for 4167 patients. A total of 12 384 geriatric recommendations were made. At least one different geriatric recommendation was implemented in 2874 patients. A dietician, social worker and geriatrician intervened most frequently for problems detected on the nutritional, social and functional domain. A total of 7569 actions were undertaken for a total of 5725 geriatric interventions, most frequently nutritional support and supplements, extended home care and psychological support. Conclusions: This large-scale Belgian study focuses on the adherence to geriatric recommendations and subsequent actions undertaken and contributes to the optimal management of older patients with cancer. We identified the domains for which geriatric recommendations are most frequently made and adhered to, and which referrals to other health care workers and facilities are frequently applied in the multidisciplinary approach of older patients with cancer.


Subject(s)
Aftercare/statistics & numerical data , Geriatric Assessment/statistics & numerical data , Guideline Adherence/statistics & numerical data , Mass Screening/statistics & numerical data , Neoplasms/diagnosis , Aftercare/standards , Aged , Aged, 80 and over , Belgium , Clinical Decision-Making , Female , Humans , Male , Mass Screening/standards , Medical Oncology/standards , Neoplasms/therapy , Practice Guidelines as Topic , Prospective Studies , Quality of Life
7.
Lett Appl Microbiol ; 65(4): 281-284, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28736948

ABSTRACT

An evaluation was made of the efficacy of 35% hydrogen peroxide vapour (HPV) against foot-and-mouth disease virus (FMDV) in a biosafety facility. Biological indicators (BIs) were produced using three serotypes of FMDV, all with a titre of ≥106 TCID50 per ml. Fifteen BIs of each serotype were distributed across five locations, throughout a 30-m3 airlock chamber, producing a total of 45 BIs. Thirty-five percent HPV was generated and applied using a Bioquell vaporization module located in the centre of the chamber. After a dwell period of 40 min, the HPV was removed via the enclosures air handling system and the BIs were collected. The surfaces of the BIs were recovered into Glasgow's modified Eagle's medium (GMEM), cultivated in BHK21 Cl13 cell culture and analysed for evidence of cytopathic effect (CPE). No CPE was detected in any BI sample. Positive controls showed CPE. The experimentation shows that FMDV is susceptible to HPV decontamination and presents a potential alternative to formaldehyde. SIGNIFICANCE AND IMPACT OF THE STUDY: Foot-and-mouth disease virus (FMDV) is an important pathogen in terms of biosafety due to its infectious nature and wide range of host animals, such as cattle, sheep, goats and pigs. Outbreaks of FMDV can have a severe impact on livestock production, causing morbidity, mortality, reduced yields and trade embargoes. Laboratories studying FMDV must possess BSL4 robust bio-decontamination methods to prevent inadvertent release. Formaldehyde has been the primary agent for environmental decontamination, but its designation as a human carcinogen has led to a search for alternatives. This study shows 35% hydrogen peroxide vapour has the potential to be a rapid, effective, residue-free alternative.


Subject(s)
Containment of Biohazards/methods , Decontamination/methods , Disease Outbreaks/veterinary , Disinfectants/pharmacology , Foot-and-Mouth Disease Virus/drug effects , Foot-and-Mouth Disease/drug therapy , Hydrogen Peroxide/pharmacology , Animals , Cattle , Cattle Diseases/prevention & control , Cattle Diseases/virology , Foot-and-Mouth Disease/virology , Goat Diseases/prevention & control , Goat Diseases/virology , Goats , Sheep , Sheep Diseases/prevention & control , Sheep Diseases/virology , Swine , Swine Diseases/prevention & control , Swine Diseases/virology
8.
J Drugs Dermatol ; 16(6): 566-572, 2017 Jun 01.
Article in English | MEDLINE | ID: mdl-28686774

ABSTRACT

BACKGROUND: There are few studies on the natural history of acne lesions including the antecedents of atrophic scars.

STUDY DESIGN: Prospective study of relationship between primary (papules, pustules, comedones) and secondary lesions (atrophic scars, macular erythema, and hyperpigmentation) over 6 months. Subjects (n=32) had moderate facial acne including 10 or more atrophic acne scars and were their own control via randomized split-face design. Lesions were mapped 2x/week for 2 months and every 2 weeks thereafter until month 6 to track pathogenic progression.

RESULTS: Clinical assessment showed acne scars continuously forming throughout the 6-month study period. While the majority (66.2%) of these scars did not resolve by study endpoint, the remainder were transient. The likelihood of a scar developing from a primary acne lesion was 5.7%, and almost all scars arose from erythematous macules or hyperpigmentation (83%) and some (16%) developed directly from papules and pustules. Duration of papules was a key factor in the risk of scarring. The majority (81.7%) of the scars remaining at 6 months were still present at 2-year follow-up.

CONCLUSIONS: Atrophic acne scars continuously form, some resolve, and evolve primarily from inflammatory and post-inflammatory lesions. Clinicians should closely monitor patients with macular erythema for scarring.

J Drugs Dermatol. 2017;16(6):566-572.

.


Subject(s)
Acne Vulgaris/complications , Acne Vulgaris/pathology , Cicatrix/etiology , Cicatrix/pathology , Erythema/complications , Erythema/prevention & control , Adolescent , Adult , Atrophy/pathology , Double-Blind Method , Face/pathology , Female , Follow-Up Studies , Humans , Hyperpigmentation/pathology , Inflammation/pathology , Male , Prospective Studies , Skin/pathology , Treatment Outcome , Young Adult
11.
J Nutr Health Aging ; 20(1): 60-70, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26728935

ABSTRACT

OBJECTIVES: The aim of this study is to describe a large-scale, Belgian implementation project about geriatric assessment (=GA) in daily oncology practice and to identify barriers and facilitators for implementing GA in this setting. Design / setting / participants: The principal investigator of every participating hospital (n=22) was invited to complete a newly developed questionnaire with closed- and open-ended questions. The closed-ended questions surveyed how GA was implemented. The open-ended questions identified barriers and facilitators for the implementation of GA in daily oncology practice. Descriptive statistics and conventional content analysis were performed as appropriate. RESULTS: Qualifying criteria (e.g. disease status and cancer type) for GA varied substantially between hospitals. Thirteen hospitals (59.1%) succeeded to screen more than half of eligible patients. Most hospitals reported that GA data and follow-up data had been collected in almost all screened patients. Implementing geriatric recommendations and formulating new geriatric recommendations at the time of follow-up are important opportunities for improvement. The majority of identified barriers were organizational, with high workload, lack of time or financial/staffing problems as most cited. The most cited facilitators were all related to collaboration. CONCLUSION: Interventions to improve the implementation of GA in older patients with cancer need to address a wide range of factors, with organization and collaboration as key elements. All stakeholders, seeking to improve the implementation of GA in older patients with cancer, should consider and address the identified barriers and facilitators.


Subject(s)
Geriatric Assessment , Hospitals , Mass Screening , Neoplasms/therapy , Aged , Aged, 80 and over , Belgium , Female , Health Services for the Aged , Health Status , Humans , Male , Middle Aged , Patient Care Planning , Surveys and Questionnaires
12.
Ultrasound Med Biol ; 41(5): 1402-10, 2015 May.
Article in English | MEDLINE | ID: mdl-25601463

ABSTRACT

Microbubble-mediated sonothrombolysis (STL) is a remarkable approach to vascular occlusion therapy. However, STL remains a complex process with multiple interactions between clot, ultrasound (US), microbubbles (MB) and thrombolytic drug. The aim of this study was to evaluate the ability of combining US and MB to degrade fibrin and, more specifically, to assess the roles of both stable (SC) and inertial (IC) cavitation. Human blood clots containing radiolabeled fibrin were exposed to different combinations of recombinant tissue plasminogen activator (rtPA), US (1 MHz) and phospholipid MB. Three acoustic pressures were tested: 200, 350 and 1,300 kPa (peak-negative pressure). Clot lysis was assessed by diameter loss and release of radioactive fibrin degradation products. The combination rtPA + US + MB clearly revealed that IC (1,300 kPa) was able to enhance fibrin degradation significantly (66.3 ± 1.8%) compared with rtPA alone (51.7 ± 2.0%, p < 0.001). However, SC failed to enhance fibrin degradation at an acoustic pressure of 200 kPa. At 350 kPa, a synergistic effect between rtPA and US + MB was observed with an absolute increase of 6% compared to rtPA alone (p < 0.001). Conversely, without rtPA, the combination of US + MB was unable to degrade the fibrin network (0.3 ± 0.1%, p > 0.05 vs. control), but induced a distinct loss of red blood cells throughout the entire thickness of the clot, implying that MB were able to penetrate and cavitate inside the clot.


Subject(s)
Blood Coagulation/physiology , Blood Coagulation/radiation effects , High-Intensity Focused Ultrasound Ablation/methods , Mechanical Thrombolysis/methods , Dose-Response Relationship, Radiation , High-Energy Shock Waves , Humans , Microbubbles , Radiation Dosage
13.
Oncogene ; 34(23): 3053-62, 2015 Jun 04.
Article in English | MEDLINE | ID: mdl-25065595

ABSTRACT

cis-Diamminedichloroplatinum(II) (CDDP), which is mostly referred to as cisplatin, is a widely used antineoplastic. The efficacy of cisplatin can be improved by combining it with the vitamin B6 precursor pyridoxine. Here, we evaluated the putative synergistic interaction of CDDP with pyridoxine in the treatment of an orthotopic mouse model of non-small-cell lung cancer (NSCLC). CDDP and pyridoxine exhibited hyperadditive therapeutic effects. However, this synergy was only observed in the context of an intact immune system and disappeared when the otherwise successful drug combination was applied to the same NSCLC cancer implanted in the lungs of athymic mice (which lack T lymphocytes). Immunocompetent mice that had been cured from NSCLC by the combined regimen of CDDP plus pyridoxine became resistant against subcutaneous rechallenge with the same (but not with an unrelated) cancer cell line. In vitro, CDDP and pyridoxine did not only cause synergistic killing of NSCLC cells but also elicited signs of immunogenic cell death including an endoplasmic reticulum stress response and exposure of calreticulin at the surface of the NSCLC cells. NSCLC cells treated with CDDP plus pyridoxine in vitro elicited a protective anticancer immune response upon their injection into immunocompetent mice. Altogether, these results suggest that the combined regimen of cisplatin plus pyridoxine mediates immune-dependent antineoplastic effects against NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/immunology , Cisplatin/administration & dosage , Lung Neoplasms/drug therapy , Lung Neoplasms/immunology , Pyridoxine/administration & dosage , Animals , Calreticulin/metabolism , Cell Line, Tumor , Drug Synergism , Drug Therapy, Combination , Endoplasmic Reticulum Stress , Mice , Mice, SCID , Neoplasm Transplantation , Xenograft Model Antitumor Assays
14.
Leukemia ; 28(4): 871-9, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24056880

ABSTRACT

In this study, we determined the respective roles of RelA and RelB NF-κB subunits in Epstein-Barr virus (EBV)-transformed B cells. Using different EBV-immortalized B-cell models, we showed that only RelA activation increased both survival and cell growth. RelB activity was induced secondarily to RelA activation and repressed RelA DNA binding by trapping the p50 subunit. Reciprocally, RelA activation repressed RelB activity by increasing expression of its inhibitor p100. To search for such reciprocal inhibition at the transcriptional level, we studied gene expression profiles of our RelA and RelB regulatable cellular models. Ten RelA-induced genes and one RelB-regulated gene, ARNTL2, were repressed by RelB and RelA, respectively. Apart from this gene, RelB signature was included in that of RelA Functional groups of RelA-regulated genes were for control of energy metabolism, genetic instability, protection against apoptosis, cell cycle and immune response. Additional functions coregulated by RelA and/or RelB were autophagy and plasma cell differentiation. Altogether, these results demonstrate a cross-inhibition between RelA and RelB and suggest that, in fine, RelB was subordinated to RelA. In the view of future drug development, RelA appeared to be pivotal in both classical and alternative activation pathways, at least in EBV-transformed B cells.


Subject(s)
Cell Transformation, Viral , Herpesvirus 4, Human/pathogenicity , Lymphoma, B-Cell/etiology , Transcription Factor RelA/physiology , Transcription Factor RelB/physiology , Cell Line , Humans , NF-kappa B/physiology , Transcription Factor RelA/antagonists & inhibitors , Transcription Factor RelA/genetics , Transcription Factor RelB/antagonists & inhibitors , Transcription Factor RelB/genetics , Transcriptome
15.
Leukemia ; 27(1): 183-9, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22944768

ABSTRACT

To clarify the relationships between marginal zone lymphomas (MZLs) and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas (WM/LPLs), immunoglobulin heavy chain variable gene (IGHV) features were analyzed and the occurrence of MYD88 L265P mutations was identified in a series of 123 patients: 53 MZLs from the spleen (SMZLs), 11 from lymph nodes (NMZLs), 28 mucosa-associated lymphatic tissue (MALT) lymphomas and 31 WM/LPLs. SMZLs were characterized by overrepresentation of IGHV1-2 gene rearrangements with a canonical motif, without selection pressure and with long CDR3 segments. NMZLs had increased frequencies of IGHV3 genes. The IGHV gene was unmutated in most cases, often with long CDR3 segments. MALT lymphomas were usually associated with a mutated IGHV gene, but with the absence of selection pressure. WM/LPLs were associated with an IGHV3-23 overrepresentation and high IGHV mutation rate, with features of selection pressure and short CDR3 segments. MYD88 L265P mutations were almost restricted exclusively to WM/LPL patients. Taken all diagnoses together, all patients with MYD88 L265P mutations had an immunoglobulin M peak and almost all patients except one had bone marrow infiltration. These results demonstrate that the history of antigen exposure of the four entities studied was different and MYD88 L265P was specifically associated with WM/LPLs. WM/LPL may thus be functionally associated with constitutive nuclear factor-κB activation.


Subject(s)
Immunoglobulin Heavy Chains/genetics , Immunoglobulin Variable Region/genetics , Lymphoma, B-Cell, Marginal Zone/genetics , Mutation/genetics , Myeloid Differentiation Factor 88/genetics , Waldenstrom Macroglobulinemia/genetics , Flow Cytometry , Gene Rearrangement , Humans , Immunoglobulin Heavy Chains/immunology , Immunoglobulin M/metabolism , Immunoglobulin Variable Region/immunology , Lymph Nodes/immunology , Lymph Nodes/pathology , Lymphoma, B-Cell, Marginal Zone/classification , Lymphoma, B-Cell, Marginal Zone/immunology , Prognosis , Splenic Neoplasms/genetics , Splenic Neoplasms/immunology , Waldenstrom Macroglobulinemia/immunology
16.
Ann Cardiol Angeiol (Paris) ; 60(4): 197-201, 2011 Aug.
Article in French | MEDLINE | ID: mdl-21665185

ABSTRACT

AIM OF THE STUDY: To assess the value of the coronary flow reserve (CFR) in the left anterior descending artery (LAD) during dobutamine stress echocardiography in the diagnosis of significant LAD stenosis (more than 70%). METHOD: Retrospective study of 81 patients with a positive stress echocardiography who underwent a coronarography. RESULTS: Measurement of coronary flow reserve was able in half echocardiographic exams. Medium Pic diastolic velocity was 0.33 m/s (SD 0.20), medium maximal diastolic velocity during stress was 0.62 m/s (SD 0.20), medium CFR was 2.25 (SD 0.65). In 50 patients LAD was not seen; in five of them LAD was occluded. The predictive positive value (PPV) of a low coronary flow reserve to detect LAD stenosis is 66.7% and the negative predictive value (NPV) is 65.4%. An abnormal anterior contraction during stress echo with a low reserve has a PPV of 75% for the diagnosis of significant IVA stenosis and a normal contraction during stress with normal coronary flow reserve means a NPV of 65%. We did not show a significant correlation between low coronary flow and abnormal contraction during stress echocardiography (kappa 0.51). CONCLUSION: Coronary flow reserve of LAD during stress echo is feasible but does not really improve exam performance to detect significant IVA stenosis. This measurement remains to be clear in coronary patients management.


Subject(s)
Coronary Circulation , Coronary Stenosis/diagnostic imaging , Coronary Stenosis/physiopathology , Coronary Vessels/diagnostic imaging , Coronary Vessels/physiology , Echocardiography, Stress , Aged , Feasibility Studies , Female , Humans , Male , Middle Aged , Retrospective Studies
17.
Ann Oncol ; 20(1): 110-6, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18701429

ABSTRACT

BACKGROUND: Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are highly aggressive diseases with a poor outcome. PATIENTS AND METHODS: We report a multicentric French retrospective study of 15 patients with relapsed, refractory, or disseminated disease, treated with L-asparaginase-containing regimens in seven French centers. Thirteen patients were in relapse and/or refractory and 10 patients were at stage IV. RESULTS: All but two of the patients had an objective response to L-asparaginase-based treatment. Seven patients reached complete remission and only two relapsed. CONCLUSION: These data, although retrospective, confirm the excellent activity of L-asparaginase-containing regimens in refractory extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia. Therefore, L-asparaginase-based regimen should be considered as a salvage treatment, especially for patients with disseminated disease. First-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia should be tested in prospective trials.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Asparaginase/administration & dosage , Leukemia/drug therapy , Lymphoma, Extranodal NK-T-Cell/drug therapy , Adult , Aged , Aged, 80 and over , Drug Resistance, Neoplasm/drug effects , Female , Humans , Leukemia/pathology , Lymphoma, Extranodal NK-T-Cell/pathology , Male , Middle Aged , Recurrence , Retrospective Studies , Treatment Outcome , Western World
19.
Food Addit Contam ; 24 Suppl 1: 122-35, 2007.
Article in English | MEDLINE | ID: mdl-17687706

ABSTRACT

Previous model studies have suggested ascorbic acid as one of the major sources of furan, a possibly hazardous compound found in thermally processed foods (e.g. canned products, jars). The study showed that about 2 mmol mol(-1) furan was obtained when dry-heating ascorbic acid, while much lower amounts were formed upon pressure cooking, i.e. 58 micromol mol(-1) at pH 4 and 3.7 micromol mol(-1) at pH 7. Model reactions also generated 2-methylfuran (MF). However, the MF levels were generally very low with the exception of the binary mixture ascorbic acid/phenylalanine (1 mmol mol(-1)). Studies with 13C-labelled ascorbic acid indicated that furan comprises an intact C4 unit, mainly C-3 to C-6, generated by splitting off two C1 units, i.e. CO2 and formic acid. Possible intermediates are 2-deoxyaldoteroses, 2-furoic acid and 2-furaldehyde, which are known as ascorbic acid degradation products. The mechanism of furan formation from ascorbic acid was validated based on the labelling pattern of furan and the identification of 13CO2 and H13COOH. Furan formation is significantly slowed down in binary mixtures, e.g. the presence of erythrose led to 80% less furan under roasting conditions. This is most likely due to competing reactions in complex systems, thus disfavouring furan formation. The mitigation effect is because furan, contrary to MF, is formed without recombination of ascorbic acid fragments. Therefore, furan levels are definitely much lower in foods than expected from trials with pure ascorbic acid. Consequently, conclusions should be drawn with much caution from model reactions, avoiding extrapolation from oversimplified model systems to food products.


Subject(s)
Ascorbic Acid/metabolism , Carcinogens, Environmental/metabolism , Food Contamination , Furans/metabolism , Amino Acids/metabolism , Carcinogens, Environmental/analysis , Cooking/methods , Dehydroascorbic Acid/metabolism , Food Analysis , Fruit/metabolism , Furans/analysis , Gas Chromatography-Mass Spectrometry/methods , Glucose/metabolism , Hot Temperature , Hydrogen-Ion Concentration , Models, Biological , Solid Phase Microextraction/methods , Tetroses/metabolism , Vegetables/metabolism
20.
Rev Med Interne ; 28(12): 885-7, 2007 Dec.
Article in French | MEDLINE | ID: mdl-17629594

ABSTRACT

We describe a 62-year-old woman with slowly growing usual nodular goitre in whom diffuse giant cell arteritis (GCA) of the thyroid arteries was found upon thyroidectomy, revealing otherwise unsuspected biopsy-proven temporal arteritis. To our knowledge, this association had been previously reported in only three instances. In each case, GCA of the thyroid arteries appeared clinically silent, did not produce significant glandular dysfunction, and was uncovered thanks to a planned thyroidectomy for nodular goitre. These observations highlight that thyroid artery involvement by GCA, even widespread, as in our patient, may be overlooked clinically and may produce little or no thyroid dysfunction.


Subject(s)
Giant Cell Arteritis/complications , Goiter, Nodular/complications , Thyroid Gland/blood supply , Vasculitis/complications , Female , Giant Cell Arteritis/pathology , Goiter, Nodular/pathology , Humans , Middle Aged , Thyroid Gland/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...